Palatin Technologies

PTN · NYSE American

$5.52−$0.47 (−7.85%)TodayMarket closed · Oct 20, 4:34 PM ET

Prev close $5.99

Latest news

NewsSep 28, 8:05 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
NewsSep 28, 8:01 AM ETAvi Kapoor
Gold Fields, Harmony Gold Mining, Anglogold Ashanti And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Press releaseSep 28, 7:30 AM ETPRNewswire
Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update
NewsSep 28, 5:29 AM ETAvi Kapoor
Why Webuy Global Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
NewsSep 1, 1:07 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
Press releaseMay 18, 4:00 PM ETPRNewswire
Palatin to Begin Trading on Nasdaq Stock Exchange
NewsMay 13, 11:31 AM ET
Transcript: Palatin Techs Q3 2026 Earnings Conference Call
Press releaseMay 13, 7:30 AM ETPRNewswire
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
NewsMar 20, 8:05 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
Press releaseFeb 17, 7:30 AM ETPRNewswire
Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
NewsNov 24, 12:05 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
NewsNov 21, 4:05 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
NewsNov 14, 12:06 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
NewsNov 13, 7:37 AM ET
Palatin Techs Q1 EPS $4.26 Up From $(0.39) YoY, Sales $8.875M
Press releaseNov 13, 7:30 AM ETPRNewswire
Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Press releaseNov 12, 12:15 PM ETPRNewswire
Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option
Press releaseNov 6, 8:00 AM ETPRNewswire
Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity
Press releaseAug 8, 4:00 PM ETPRNewswire
Palatin Announces 1-for-50 Reverse Stock Split
NewsJul 23, 7:30 AM ETVandana Singh
Abivax Stock Skyrockets On Strong Data From Inflammatory Bowel Disorder Study
Press releaseMay 14, 7:30 AM ETPRNewswire
Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update
Press releaseMay 9, 7:30 AM ETPRNewswire
Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025
Press releaseMay 8, 10:19 PM ETPRNewswire
Palatin Technologies Announces Closing of Reduced Public Offering
Press releaseMay 8, 4:39 PM ETPRNewswire
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025
Press releaseMay 7, 8:26 PM ETPRNewswire
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice
NewsMay 7, 1:06 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
Press releaseMay 7, 8:15 AM ETPRNewswire
Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice
NewsMay 7, 8:09 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Press releaseMay 7, 8:00 AM ETPRNewswire
Palatin Technologies Announces Pricing of up to $23 Million Public Offering
Press releaseMay 5, 7:30 AM ETPRNewswire
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy
Press releaseApr 29, 7:30 AM ETPRNewswire
Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease
Press releaseApr 17, 7:30 AM ETPRNewswire
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide
Press releaseApr 14, 7:00 AM ETPRNewswire
Palatin Appeals NYSE American Notice of Delisting
Press releaseApr 10, 4:01 PM ETPRNewswire
Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal
Press releaseApr 10, 7:30 AM ETPRNewswire
Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting
Press releaseMar 31, 7:30 AM ETPRNewswire
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
Press releaseMar 28, 7:30 AM ETPRNewswire
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
Press releaseMar 25, 7:30 AM ETPRNewswire
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

12 Health Care Stocks Moving In Monday's Pre-Market Session

Gold Fields, Harmony Gold Mining, Anglogold Ashanti And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update

Why Webuy Global Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Tuesday's Intraday Session

Palatin to Begin Trading on Nasdaq Stock Exchange

Transcript: Palatin Techs Q3 2026 Earnings Conference Call

Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

12 Health Care Stocks Moving In Friday's Pre-Market Session

Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Friday's After-Market Session

12 Health Care Stocks Moving In Friday's Intraday Session

Palatin Techs Q1 EPS $4.26 Up From $(0.39) YoY, Sales $8.875M

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option

Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity

Palatin Announces 1-for-50 Reverse Stock Split

Abivax Stock Skyrockets On Strong Data From Inflammatory Bowel Disorder Study

Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update

Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025

Palatin Technologies Announces Closing of Reduced Public Offering

Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice

12 Health Care Stocks Moving In Wednesday's Intraday Session

Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Palatin Technologies Announces Pricing of up to $23 Million Public Offering

Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy

Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Palatin Appeals NYSE American Notice of Delisting

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency